IP Library Granted Patent US 10,881,613
Granted Patent B2
US 10,881,613 · App. 16/084,769 · Granted Jan 5, 2021

Fumarate polymersomes

Inventor: Giuseppe Battaglia (London, GB)
Assignee: UCL BUSINESS LTD
A61K9/1273A61K31/704A61K47/34A61P17/06A61P19/02A61P25/00A61P35/02A61P37/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,881,613
App. No.
16/084,769
Granted
Jan 5, 2021
Kind
B2
Abstract

The present invention relates to fumarate polymersomes. The polymersomes are capable of targeting immune cells and then hydrolysing to release the immunomodulatory compound fumarate. The polymersomes can thus be used methods for the treatment of prevention of diseases, including immune diseases such as multiple sclerosis and psoriasis.

Claims (24)

1. A polymersome that comprises an amphiphilic block copolymer comprising a hydrophilic block and a hydrophobic block, wherein:

(a) the hydrophilic block comprises a phosphorylcholine polymer; and

(b) the hydrophobic block comprises a fumarate polymer;

further wherein the polymersome is configured to release fumarate as an active agent at a desired site of action by in situ hydrolysis.

2. The polymersome of claim 1 , wherein the phosphorylcholine polymer is an acrylate polymer.

3. The polymersome of claim 2 , wherein the acrylate polymer comprises units of formula (I)

in which R p is hydrogen or methyl and A p is a group of formula (I′)

in which X p is a C 1-6 alkylene group.

4. The polymersome of claim 1 , wherein the phosphorylcholine polymer is poly(2-(methacryloyloxy)ethyl phosphorylcholine).

5. The polymersome of claim 1 , wherein the fumarate polymer comprises a fumarate unit of formula (II)

6. The polymersome of claim 1 , wherein the fumarate polymer comprises repeating units of formula (III)

wherein Y p is a straight chain or branched C 1-6 alkylene group.

7. The polymersome of claim 1 , wherein the fumarate polymer is poly(propylene fumarate).

8. The polymersome of claim 1 , which further comprises a drug encapsulated within the polymersome.

9. The polymersome of claim 8 , wherein the drug is an immunomodulator.

10. The polymersome of claim 8 , wherein the drug is an anti-cancer compound.

11. A pharmaceutical composition comprising: a plurality of polymersomes; and one or more pharmaceutically acceptable excipients or diluents; wherein each polymersome of the plurality of polymersomes comprises an amphiphilic block copolymer comprising a hydrophilic block and a hydrophobic block, wherein:

(a) the hydrophilic block comprises a phosphorylcholine polymer; and

(b) the hydrophobic block comprises a fumarate polymer;

further wherein each polymersome of the plurality of polymersomes is configured to release fumarate as an active agent at a desired site of action by in situ hydrolysis.

12. A method comprising administering a therapeutically effective amount of a polymersome to a subject, wherein the polymersome comprises an amphiphilic block copolymer comprising a hydrophilic block and a hydrophobic block, wherein:

(a) the hydrophilic block comprises a phosphorylcholine polymer; and

(b) the hydrophobic block comprises a fumarate polymer;

further wherein the method comprises the release of fumarate as an active agent from the polymersome at a desired site of action by in situ hydrolysis.

Assignments (2)
CHANGE OF NAME Recorded Nov 20, 2020
From: UCL BUSINESS PLC
To: UCL BUSINESS LTD
Reel/Frame 054490/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2019
From: BATTAGLIA, GIUSEPPE
To: UCL BUSINESS PLC
Reel/Frame 049281/0040 →
Priority Claims (1)
GB 1604553.6 · Mar 17, 2016 · national
Continuity (1)
Related Publication 20190076359A1 · Mar 14, 2019